Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sulthiame in Obstructive Sleep Apnea (FLOW)
NCT05236842Phase 2Completed
- Sponsor
- Desitin Arzneimittel
- Start
- Nov 2021
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sultiame in obstructive sleep apnea (OSA) (4 arms), sponsored by Desitin Arzneimittel. Primary endpoint: Relative change in Apnea-Hypopnea Index at 15 weeks. Started Nov 2021; status: completed.
02
Drugs
sultiame
03
Conditions
obstructive sleep apnea (OSA)
Beyond the preview
Go deeper on NCT05236842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05236842.